FDA Orange Book · active-ingredient family
Boceprevir
Boceprevir is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:VICTRELIS · NDA 202258
1
Brand (NDA)
0
Generics (ANDA)
2
Listed patents
0
Exclusivity periods
Brand (NDA) products · capsule
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| VICTRELIS | MERCK SHARP DOHME | NDA 202258 | — | May 13, 2011 |
Listed patents (2)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8119602 | Mar 17, 2027 | in 9 mo | U-1233 |
| 7772178 | Nov 11, 2027 | in 1 yr 5 mo | ProductU-1128 |
Boceprevir — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
